Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Porustobart - Harbour BioMed

Next Previous
Drug Profile

Porustobart - Harbour BioMed

Alternative Names: HBM-4003; HCAb-4003-2

Latest Information Update: 11 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harbour BioMed
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Liver cancer; Neuroendocrine tumours; Renal cell carcinoma; Solid tumours
  • Phase I/II Malignant melanoma
  • No development reported Non-small cell lung cancer

Most Recent Events

  • 10 Sep 2026 Updated efficacy data from a phase II trial in Solid tumours released by Harbour BioMed
  • 09 Sep 2026 Solstice Oncology plans phase II trial in Colorectal cancer (Neoadjuvant therapy, Combination therapy, Late stage disease) in US, Belgium, Italy, Netherlands, Spain and United Kingdom in September 2026 (IV) (NCT07808151)
  • 22 Oct 2025 Efficacy and adverse event data from a phase II trial in Solid tumours released by Harbour BioMed

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top